Nanobac Pharmaceuticals, Inc. Announces the Much Anticipated Release of `Has Heart Disease Been Cured?'.

Business Editors/Health/Medical Writers

TAMPA, Fla.--(BUSINESS WIRE)--Nov. 25, 2003

Nanobac Pharmaceuticals, Inc. (OTCPK:NNBP) ("Nanobac" or "The Company") announced today that the book described in its September 15, 2003 press release, Has Heart Disease Been Cured?, an independent publication by the Writers' Collective, has been published. The book, authored by Douglas Mulhall and Katja Hansen, presents significant information about the company's technology and the future of Nanobacteria research and development.

The following is reprinted with permission from the Writers' Collective:

NEWS ADVISORY FROM THE WRITERS' COLLECTIVE PUBLISHERS

EMBARGOED UNTIL NOVEMBER 20, 2003

"HAS HEART DISEASE BEEN CURED?"

What may be the most revolutionizing discovery in the history of heart disease treatment is chronicled in a new book, Has Heart Disease Been Cured? by acclaimed science journalist Douglas Mulhall and biological engineer co-author Katja Hansen.

The Foreword is written by one of America's leading conservative cardiologists, Dr. Benedict S. Maniscalco, founder of St. Joseph's Hospital Heart Institute.

Doctors have long suspected that infection plays a role in heart disease, but while many germs are known to accompany it, treating them did not halt the illness. Until now. Researchers have since identified a "stealth" infection and developed a compound of surprisingly well-known drugs that gradually get rid of it.

The sub-microscopic invader was discovered in 1985, but only isolated in heart disease in 1999. That finding was just published in 2002. A treatment was developed and has been prescribed to thousands of seriously ill patients since 2001 by physicians across the United States, with encouraging results.

"The most persistent question about this book," explains publisher Lisa Grant, "will undoubtedly be...why didn't we hear about the discovery earlier?"

"Here's a clue. According to the Center for Disease Control, for years the medical community was slow to acknowledge that in the 1980's bacteria were found to be responsible for most stomach ulcers. Until the mid-1990's, surgeons continued operating on patients unnecessarily, despite the existence of a known drug treatment."

"This book warns that we risk repeating history if an infection of such deep importance for heart disease is given low priority."

The thoroughly annotated work is written in plain language for lay readers. It contains a glossary of technical terms, along with illustrations, a chronology of related discoveries, and a "who's who" of participants in the breakthrough. These are additional to the customary bibliography, endnotes, and index.

The book has already been featured on syndicated radio talk shows, and will be introduced at a Special Presentation sponsored by community health authorities and the Palm Beach County Library System in Palm Beach, Florida in early December.

Has Heart Disease Been Cured? (Writers' Collective, 2003) Douglas Mulhall and Katja Hansen Foreword by Benedict S. Manicalco, M.D., F.A.C.C. ISBN 1-932133-73-9 288 pages, Trade Paperback, Illustrations, Index, Bibliography, Endnotes, Glossary

Publishing date: November 21, 2003

Douglas Mulhall's previous work, "Our Molecular Future: How Nanotechnology, Robotics, Genetics and Artificial Intelligence Will Transform our World," was selected by New Scientist for the magazine's "must read" list, praised by the American Library Association as an "Outstanding Academic Title," and put on the "recommended" lists of several national booksellers. International media such as Financial Times Publications, NewsDay, The Futurist, Futures Research Quarterly, and National Post have published his articles. For years, he and Katja Hansen managed scientific research on eliminating water-borne infections.

To order a reviewers copy or arrange an interview with authors:

Fritz Stork 21st Century Eloquence, Distributors email: [e-mail] Tel. [phone]

To contact the publisher: Lisa Grant, Publisher The Writers' Collective, Cranston, Rhode Island http://www.writerscollective.org Email: [e-mail]

For more information about the topic, and to order the book, log onto http://www.calcify.com.

Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida, U.S.A. For more information, please visit our website at http://www.nanobaclabs.com or contact us at [e-mail].

Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which might cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report, these statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.